Adagene Inc
NASDAQ:ADAG

Watchlist Manager
Adagene Inc Logo
Adagene Inc
NASDAQ:ADAG
Watchlist
Price: 2.05 USD 1.99%
Market Cap: 90.8m USD
Have any thoughts about
Adagene Inc?
Write Note

Adagene Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adagene Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Adagene Inc
NASDAQ:ADAG
Cash from Operating Activities
-$28.5m
CAGR 3-Years
0%
CAGR 5-Years
-15%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash from Operating Activities
-ÂĄ7.8B
CAGR 3-Years
-15%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Cash from Operating Activities
ÂĄ555.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash from Operating Activities
ÂĄ1.5B
CAGR 3-Years
49%
CAGR 5-Years
49%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash from Operating Activities
ÂĄ3.3B
CAGR 3-Years
-29%
CAGR 5-Years
24%
CAGR 10-Years
36%
Imeik Technology Development Co Ltd
SZSE:300896
Cash from Operating Activities
ÂĄ2B
CAGR 3-Years
66%
CAGR 5-Years
71%
CAGR 10-Years
N/A
No Stocks Found

Adagene Inc
Glance View

Market Cap
90.8m USD
Industry
Biotechnology

Adagene, Inc. engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

ADAG Intrinsic Value
0.96 USD
Overvaluation 53%
Intrinsic Value
Price

See Also

What is Adagene Inc's Cash from Operating Activities?
Cash from Operating Activities
-28.5m USD

Based on the financial report for Dec 31, 2023, Adagene Inc's Cash from Operating Activities amounts to -28.5m USD.

What is Adagene Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-15%

Over the last year, the Cash from Operating Activities growth was 41%.

Back to Top